The introduction of PTX in the therapy scheme of L1CAM-targeted 177Lu-DOTA-chCE7 RIT may provide a potential clinical setup against residual ovarian tumour nodules after first-line tumour resection. The gene discussed is L1CAM; the disease is ovarian neoplasm.